Merck has patented a tablet containing a compound of Formula I in a water-soluble polymer matrix with a disintegration system for rapid release. GlobalData’s report on Merck gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Merck, Human telomerase RT biomarker was a key innovation area identified from patents. Merck's grant share as of February 2024 was 54%. Grant share is based on the ratio of number of grants to total number of patents.
Fast disintegrating tablet with compound of formula ia
The granted patent (Publication Number: US11925709B2) discloses a tablet comprising an extrudate with a water-soluble polymer matrix, a dispersing agent, and a compound of Formula Ia or a pharmaceutically acceptable salt thereof. The water-soluble polymer matrix in the tablet is specified to be a water-soluble polyvinylpyrrolidone/vinyl acetate (PVP-VA) copolymer, while the disintegration system includes a disintegrant like croscarmellose sodium or crospovidone. The dispersing agent can be d-alpha tocopherol polyethyleneglycol succinate (TPGS) or polyethoxylated castor oil, with a preference for TPGS. The compound of Formula Ia is present in a specific range of about 20 wt % to about 22 wt % of the extrudate, which itself constitutes about 50 wt % of the tablet.
Furthermore, the tablet's hardness is defined to be from about 12 kP to about 18 kP, and an additional disintegration system component of powdered sodium chloride may be included. These specific compositions and proportions outlined in the patent claims aim to provide a tablet formulation with controlled release properties and improved bioavailability. The use of the specified materials and their respective quantities in the tablet's composition is crucial for achieving the desired pharmaceutical effects and ensuring the tablet's structural integrity and disintegration properties. This patent highlights the importance of precise formulation in pharmaceutical development to enhance drug delivery systems and optimize therapeutic outcomes for patients.
To know more about GlobalData’s detailed insights on Merck, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
